top of page

Pfizer, BioNTech claims COVID-19 Vaccine is 95% Effective

Photo by

A COVID-free Christmas might be coming to town after Pfizer and BioNTech said, that their data on the completed analysis on the COVID-19 vaccine experiment is found to be efficient and consistent across all age groups, genders, and ethnicities. It is also announced that they were applying for US emergency approval within days.

The world’s hope was kept high in bringing back the old normal when Pfizer and its German partner announced that their preliminary analysis showed that the vaccine was 90% effective.

According to Pfizer’s CEO Albert Bourla, "The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,"


The news came after 170 people fell sick in an ongoing clinical trial of almost 44,000 people which is only 0.39% of the said number. 162 people were in a placebo group and 8 of them received the two-dose medicine.

Out of the 170 patients who became sick, 10 developed severe COVID-19 – 9 in the placebo group and one in the vaccine group.

The new data showed the vaccine was tolerable, with most side-effects short-lived and either mild or moderate. The preliminary analysis announced last week had been based on data from 94 sick people, and the companies say the additional patients have now given them a more developing picture.

The trial for the vaccine’s efficacy will continue for another two years to find out how long immunity lasts and whether there are long term safety issues.

If the FDA issues an emergency use authorization, the vaccine could start reaching the first Americans especially the frontline workers, the elderly, and those who are at a higher risk during the first half of December.

The said Pharmaceuticals claimed that they expect to produce 50 million doses this year and 1.3 billion by the end of 2021.


6 views0 comments
bottom of page